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A B s t R A c t
the availability of nucleoside analogues has broadened 
treatment options for chronic hepatitis B virus (HBV) 
infection. Registered treatment for chronic hepatitis B 
currently consists of (pegylated) interferon, lamivudine 
and adefovir, while entecavir is expected to be licensed in 
the short term. treatment is generally recommended for 
patients with high serum HBV DNA and elevated ALAt, 
indicating the host’s immune response against HBV. 
Induction of an HBV-specific immune response seems 
crucial for persistent control of HBV infection. currently 
available treatment strategies can be differentiated into 
those that provide sustained off-treatment response 
and those that provide therapy maintained response. 
A finite treatment course with immunomodulatory agents 
(interferon-based therapy) results in sustained response 
in about one third of patients, while nucleoside analogue 
treatment generally requires indefinite therapy without 
a clear stopping point. since nucleoside analogues are 
well tolerated, prolonged therapy is feasible, but a major 
drawback is the considerable risk of developing antiviral 
resistance, which occurs most frequently in lamivudine-
treated patients and to a lesser extent during adefovir 
or entecavir therapy. In our opinion, treatment with 
peginterferon should therefore be considered first-line 
therapy in eligible patients with a high likelihood of 
response based on serum HBV DNA, ALAt and HBV 
genotype. Patients not responding to PEG-IFN therapy or 
not eligible for peginterferon therapy should be treated with 
nucleos(t)ide analogues. 
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I N t R o D u c t I o N
Worldwide more than two billion people have been infected 
with hepatitis B virus (HBV) and chronic HBV infection 
affects about 400 million people.1,2 It is estimated that 
more than 500,000 people die annually due to HBV-
associated liver disease, largely because of cirrhosis and/or 
hepatocellular carcinoma.3 Despite the availability of safe 
and effective vaccines for more than two decades, HBV 
infection is still a global health problem. The approach to 
the treatment of chronic HBV infection has dramatically 
changed over the past decade and the current availability 
of a number of antiviral drugs adds to the complexity 
of management of chronic HBV. This paper provides a 
practical review of available treatment options to guide 
decisions on optimal therapy based on both patient and 
treatment characteristics. The main focus will be on 
deciding between a finite course of immunomodulatory 
therapy with (pegylated) interferon (IFN) or prolonged viral 
suppression with nucleoside analogues. 
Natural history
In adults, infection with HBV is usually asymptomatic 
and results in chronic infection in <5% of patients.3 
Infection at younger age is associated with a higher 
risk of chronic infection, up to 90% in the setting of 
perinatal transmission.3 Patients can present with chronic 
HBV in one of four phases of infection (figure 1).4 In the 
immunotolerant phase of infection, hepatitis B surface 
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antigen (HBsAg) and hepatitis B e antigen (HBeAg) are 
present and HBV DNA levels are high, >1.0 x 105 copies per 
millilitre (c/ml). Hepatic inflammation is mild with normal 
or minimally elevated serum alanine aminotransferase 
(ALAT) levels and minimal necroinflammation on liver 
histology. In the immuno-active phase, HBsAg, HBeAg and 
high HBV DNA are still present, while an active immune 
response results in hepatic inflammation with elevation of 
serum ALAT. In the immune-clearance phase HBeAg is 
present and HBV DNA levels can be high or fluctuating. 
Liver inflammation is present with elevated serum ALAT and 
active inflammation on liver histology; loss of HBeAg and 
seroconversion to anti-HBe can occur. The immune-control 
phase follows HBeAg seroconversion. In this phase hepatic 
inflammation is minimal and HBV DNA levels are low due to 
continuous host immune response. This phase of infection is 
also referred to as the ‘inactive carrier state’. In an increasing 
number of patients with HBeAg-negative HBV, biochemical 
and histological activity recur and HBV DNA levels are 
high, resulting in HBeAg-negative chronic hepatitis. These 
patients often originate from the Mediterranean basin, 
and are infected with hepatitis B variants that hamper 
the production of HBeAg. The most commonly described 
mutation is a G to A transition at position 1896 of the precore 
region. Three major patterns of HBeAg-negative HBV can 
be distinguished: a recurrent form with exacerbations and 
periods of remission (45%), an unremitting form (36%), and 
an unremitting form with acute exacerbations (20%).5 
Despite the occurrence of HBeAg-negative HBV, 
HBeAg seroconversion is still usually associated with 
improved long-term outcome and therefore considered an 
important event in the natural course of chronic HBV.6 
Spontaneous HBeAg seroconversion occurs in 8 to 15% of 
patients in Western countries.3 Before achieving HBeAg 
seroconversion many patients have episodes of acute 
exacerbation.7,8 The chance of HBeAg seroconversion 
during acute exacerbation increases with increasing serum 
ALAT levels, to 45% in patients with ALAT >5 times the 
upper limit of normal (ULN).9,10
Progression to cirrhosis
The overall annual incidence of progression to cirrhosis 
in chronic HBV-infected patients is about 6%, with a 
cumulative five-year probability of 20%.11 In HBeAg-
positive patients the annual incidence of progression to 
cirrhosis is 2 to 5%.3 Factors associated with an increased 
rate of progression to cirrhosis include high serum HBV 
DNA, coinfection with hepatitis C virus (HCV), hepatitis 
D virus (HDV) or human immunodeficiency virus (HIV), 
recurrent episodes of acute exacerbation and severe 
necroinflammation at diagnosis.3,12-14 The probability of 
survival five years after diagnosis of cirrhosis is 84%.15 
Hepatic decompensation occurs at an annual rate of 
about 3% in cirrhotic patients, with a five-year cumulative 
incidence of 16%.3 Development of decompensated cirrhosis 
is associated with survival of only 35% at five years.16
Hepatocellular carcinoma
The development of hepatocellular carcinoma (HCC) is 
a major global health problem.17 Cirrhosis predisposes to 
HCC and the majority of patients with HCC have underlying 
cirrhosis (80 to 90%).18 The annual incidence of HCC in 
European patients with chronic hepatitis B is about 2.2% 
in patients with compensated cirrhosis, with a five-year 
cumulative incidence of about 10%.18 In Asians the incidence 
of HCC is higher with an annual rate of 3.2% in patients 
with cirrhosis and a five-year cumulative incidence of 15%.18 
Predictors of the occurrence of HCC in cirrhotic patients 
include older age, male sex, sustained activity of liver 
disease, high HBV DNA level, HBeAg positivity, coinfection 
with HCV or HIV and alcohol abuse.18-21 Screening for HCC, 
with monitoring of α-fetoprotein levels and six-monthly 
radiographic examination should be considered for patients 
at increased risk of developing HCC.22
Hepatitis B virus genotypes
Hepatitis B virus has been classified into eight genotypes 
(A-H) (table 1).23-25 Genotypes A and D are most frequently 
observed in Europe and North America, while genotypes 
B and C are prevalent in Asia. Compared with genotype 
C, genotype B is associated with spontaneous HBeAg 
seroconversion at younger age, less active liver disease, a 
slower rate of progression to cirrhosis and less frequent 
development of HCC.26-28 Findings on the relationship of 
other genotypes with clinical outcome are contradictory.29,30 
HBV genotype has been reported to be associated with 
Figure 1. Natural history of chronic hepatitis B 
infection
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this figure shows the phases in chronic hepatitis B infection. 
Patients can be categorised in one of these four phases depending 
on serum HBV DNA and ALAt, and the presence or absence of 
HBeAg and anti-HBe.
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response to (pegylated) interferon treatment. HBeAg 
seroconversion was found to occur more often in patients 
with genotype A and B than in those with genotype C 
and D.31-33 Genotype B seems to have a better virological 
response to lamivudine than genotype C.34
Hepatitis B virus immunopathogenesis
Hepatitis B virus specific T-cell response plays a crucial 
role in control of viral infection. A vigorous, polyclonal 
and multispecific peripheral blood T-cell response can 
be observed in patients with acute self-limiting HBV.35,36 
Activated HBV-specific helper and cytotoxic T-cells are still 
present several years after recovery from acute hepatitis B 
and seem to be maintained by continuous stimulation by 
minute amounts of persisting virus. Therefore, resolution 
of disease does not imply complete eradication of infection 
but merely reflects the capacity of HBV-specific T-cells to 
persistently control HBV infection.37,38 Viral persistence is 
believed to be associated with functional tolerance of helper 
T-lymphocytes and cytotoxic T-lymphocytes to HBV.39 
In chronic HBV-infected patients levels of HBV-specific 
helper T-cells and cytotoxic T-lymphocytes are generally 
very low or undetectable.35
M A N A G E M E N t  o F  c H R o N I c 
H E P A t I t I s  B  V I R u s  I N F E c t I o N
Patients eligible for antiviral treatment
Antiviral treatment is, in general, not recommended 
for patients with acute hepatitis B, since the outcome 
of acute hepatitis B is good in the vast majority of 
immunocompetent adult patients. For HBeAg-positive 
patients, treatment is recommended for chronically 
infected patients with HBV DNA >105 c/ml and persistence 
of elevated ALAT levels (more than twice the upper limit 
of normal) over a three to six month period (table 2). An 
HBV DNA level of 104 c/ml should be used for HBeAg-
Buster, et al. Antiviral treatment for chronic hepatitis B virus infection.
table 1. Geographical distribution of hepatitis B virus genotypes
Genotype subtypes Geographical distribution
A adw2, ayw1 North-Western Europe, Spain, Poland, USA, Central Africa, India, Brazil
B adw2, ayw1 Southeast Asia, Taiwan, Japan, Indonesia, China, Hong Kong, Vietnam, Thailand
C adw2, adrq+, adrq-, ayr Far East Asia, Taiwan, Japan, Korea, China, Hong Kong, Thailand,
Indonesia, Polynesia, Solomon Islands, Vietnam, India, Australia, USA, Brazil
D ayw2, ayw3 Mediterranean area, Albania, Middle East, Turkey, Iran, India, Spain, Czech, Russia, 
USA, Brazil, Solomon Islands
E ayw4 West Africa
F adw4q-, adw2, ayw4 Central and South America, Bolivia, Venezuela, Argentina, Brazil, Polynesia, Alaska
G adw2 France, Germany, USA
H adw4 Central and South America
this table shows the association of eight hepatitis B virus genotypes with various subtypes and geographic distribution according to genotype.
table 2. Management strategies in chronic hepatitis B
stage of disease HBeAg status ALAt HBV DNA (c/ml) Management strategy
Compensated  
liver disease
HBeAg positive ≥2x ULN ≥1.0 x 105 Antiviral treatment indicated (PEG-IFN or 
nucleos(t)ide analogue therapy)
<2x ULN ≥1.0 x 105 3 monthly monitoring, consider liver biopsy (consider 
treatment in case of active necroinflammation) 
<2x ULN <1.0 x 105 3 monthly monitoring
≥2x ULN <1.0 x 105 Exclude other causes of hepatitis, consider liver biopsy
HBeAg negative ≥2x ULN ≥1.0 x 104 Antiviral treatment indicated (PEG-IFN or 
nucleos(t)ide analogue therapy)
<2x ULN ≥1.0 x 104 3-6 monthly monitoring, consider liver biopsy (consider 
treatment in case of active necroinflammation) 
<2x ULN <1.0 x 104 6-12 monthly monitoring
≥2x ULN <1.0 x 104 Exclude other causes of hepatitis, consider liver biopsy
Decompensated 
liver disease
HBeAg positive Any level Positive by PCR 
(>300) 
Antiviral treatment indicated (nucleos(t)ide analogue 
therapy)
HBeAg negative Any level Positive by PCR 
(>300) 
Antiviral treatment indicated (nucleos(t)ide analogue 
therapy)
this table shows management strategies for chronic hepatitis B infected patients based on the stage of liver disease, HBeAg status, HBV DNA level 
and serum alanine aminotransferase (ALAt). For patients with no treatment indication at this moment, monitoring of these variables at various 
intervals is recommended. uLN = upper limit of normal; PcR = polymerase chain reaction.
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negative patients, since this level was found to differentiate 
patients from having HBeAg-negative chronic hepatitis 
or being inactive carriers.40 In HBeAg-negative patients 
with HBV DNA >104 or HBeAg-positive patients with HBV 
DNA >105 c/ml, and presence of normal ALAT levels, a liver 
biopsy may be considered to guide decisions on antiviral 
therapy.41 In case of active necroinflammation, antiviral 
treatment can be considered. In patients with histological or 
clinical evidence of advanced fibrosis or cirrhosis, treatment 
with lamivudine has shown to reduce progression to 
decompensated liver disease and hepatocellular carcinoma.42 
Since serum HBV DNA has become increasingly important 
in the management of chronic HBV, use of standardised 
assays for quantification of HBV DNA is essential.
Patients who are currently not candidates for treatment 
should be monitored, as their condition may run a 
fluctuating course and treatment may be needed on 
future examinations (table 2). For HBeAg-positive 
patients with high serum HBV DNA but normal ALAT 
levels, monitoring ALAT with three monthly intervals 
is recommended, with more frequent monitoring when 
ALAT levels become elevated. Testing for liver chemistry 
should be performed every six to twelve months to account 
for reactivation of liver disease in HBeAg-negative patients 
with low serum HBV DNA and normal ALAT levels.43
Goals of therapy
Sustained viral suppression is the key to reduce hepatic 
necroinflammation and progression of liver fibrosis. Since 
elimination of HBV infection (HBsAg seroconversion) can 
only be achieved in a small proportion of patients with 
currently available antiviral agents, permanent suppression of 
HBV is the primary goal of treatment. Further, seroconversion 
to anti-HBe should be pursued in HBeAg-positive patients 
since this is associated with improved outcome.44,45
Definition of response to antiviral treatment
Response to antiviral treatment can be defined as sustained 
off-therapy or therapy-maintained response. Biochemical 
response is defined as decrease in serum ALAT to within 
the normal range. A virological response is defined 
as HBV DNA <105 c/ml or HBV DNA negativity by 
sensitive molecular assays, and loss of HBeAg in previously 
positive patients.3 Histological response is best defined as 
a two-point decrease in necroinflammatory score with no 
worsening of fibrosis. Complete response is defined as loss 
of HBsAg with appearance of anti-HBs.
treatment of chronic hepatitis B 
Two major types of antiviral drugs are being used for the 
treatment of chronic HBV: drugs that directly interfere with 
virus replication and drugs that modulate the HBV-specific 
immune response. Nucleoside and nucleotide analogues, such 
as lamivudine, adefovir and entecavir, directly inhibit reverse 
transcriptase and thereby impair viral replication. Interferon 
(IFN) has marked immunomodulatory, but less pronounced 
direct antiviral effects. Registered treatment for chronic HBV 
in most countries currently consists of interferon-alpha, 
lamivudine, adefovir, peginterferon-a-2a and entecavir, of 
which the last two have recently been approved. Approval 
of entecavir for the treatment of chronic HBV in Europe is 
expected on the short term. Advantages and limitations of, 
and response to a one-year course of treatment with these 
antiviral agents, as well as factors influencing likelihood of 
response, are shown in tables 3 and 4.
I M M u N o M o D u L A t o R y  D R u G s
Pegylated interferon-a
Interferon-alpha (IFN-a) was licensed for the treatment 
of chronic hepatitis B in most countries in the early 
1990s. Interferons are naturally occurring cytokines 
with immunomodulatory, antiproliferative and antiviral 
properties.46
In HBeAg-positive patients IFN-a results in loss of HBeAg 
in 25 to 40% of patients.44,47-52 The majority of patients 
have a durable response; reactivation occurs in 10 to 
20% of patients.44,53,54 Standard IFN-a induced responses 
are less durable in HBeAg-negative chronic HBV, with 
sustained response in 10 to 47% (average 24%) at 12 months 
after cessation of therapy.55-59 Long-term follow-up studies 
showed better overall survival and lower incidence of 
hepatic decompensation and HCC in responders to IFN-a 
therapy.44,45,54,60 
The addition of a polyethylene glycol (PEG) molecule to IFN 
significantly prolongs half-life and results in more sustained 
IFN activity. Two pegylated IFNs have been studied for the 
treatment of HBV, a large branched 40kDa PEG linked to 
IFN a-2a (peginterferon a-2a) and a small linear 12kDa 
PEG linked to IFN a-2b (peginterferon a-2b).61 Both these 
interferons were initially investigated for the treatment 
of chronic hepatitis C infection and have shown similar 
tolerability and higher rates of sustained viral response 
compared with conventional IFN.62,63 Peginterferon-alpha-2a 
(PEG-IFN a-2a) has recently been registered for the treatment 
of chronic HBV in Europe and the United States and should 
be given by subcutaneous injection once weekly for 48 weeks 
in a dosage of 180 microgram in both HBeAg-positive and 
HBeAg-negative patients. Results of treatment with PEG-
IFN during shorter periods are very limited. Peginterferon-
alpha-2b (PEG-IFN a-2b) will only be registered in specific 
east-Asian countries.
In HBeAg-positive patients treatment with PEG-IFN was 
found superior to conventional IFN, with loss of HBeAg 
in 35% and seroconversion to anti-HBe in 29 to 32% of 
patients.32,64-66 Long-term follow-up of patients treated with 
PEG-IFN and lamivudine combination therapy showed 
Buster, et al. Antiviral treatment for chronic hepatitis B virus infection.
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durable response at 72 weeks post-treatment in over 80% 
of responders.67 In HBeAg-negative HBV only one large 
randomised controlled trial using PEG-IFN has been 
conducted so far.68 At the end of follow-up, a combined 
response, with suppression of serum HBV DNA below 
104 c/ml and normalisation of ALAT, was observed in 36% of 
patients. HBsAg seroconversion occurs in 3 to 7% of PEG-IFN 
treated patients, which represents 10 to 20% of virological 
responders.32,64,68 HBV genotype appears to predict response 
to PEG-IFN, with a higher probability of HBeAg loss and 
HBsAg loss for patients with genotype A (47 and 14%) and B 
(44 and 9%) compared with genotype C (28% and 3%) and 
D (25 and 2%).32,65,69 Addition of a nucleoside analogue to 
PEG-IFN therapy does not increase response rates in either 
HBeAg-positive or HBeAg-negative patients, as has earlier 
been shown in conventional IFN therapy.32,64,68,70
Interferon can have several side effects including influenza-
like symptoms, fatigue, headache, myalgia, gastrointestinal 
symptoms (nausea, anorexia, weight loss), alopecia and local 
reaction at the injection site. These side effects are frequently 
observed, but rarely lead to discontinuation of treatment. 
More serious adverse events such as myelosuppression, 
neuropsychiatric symptoms (irritability, depression and 
insomnia), neurological symptoms and thyroid dysfunction 
may require dose reduction or discontinuation.71,72 Use of 
PEG-IFN is not recommended in advanced liver disease 
Buster, et al. Antiviral treatment for chronic hepatitis B virus infection.
table 3. Comparison of drugs approved for the treatment of chronic hepatitis B
HBeAg positive HBeAg negative
HBeAg seroconversion HBV DNA negativity
treatment Advantage Disadvantage Eot EoFu Eot EoFu
Alpha-interferon Finite treatment course
No drug resistance
Frequent subcutaneous 
injection
Frequent adverse events
Contraindicated in 
advanced cirrhosis
High costs
35%
(44, 47-51)*
30%
(44, 47-51,  
53, 65)*
60%
(55-59, 119, 
120)*
35%
(55-59)*
Peginterferon Finite treatment course
Weekly dosage interval
No drug resistance
Subcutaneous injection
Frequent adverse events
Contraindicated in 
advanced cirrhosis
High costs
40%
(32, 64-66)*
35%
(32, 64-67)*
63%
(68)* 
19%
(68)*
Lamivudine Oral administration
Good tolerability
Low costs
Long duration of 
treatment
High incidence of 
antiviral resistance
19%
(74-78)*
12%
(67, 83, 84)*
65%
(68, 85, 87)* 
10%
(68, 86)*
Adefovir Oral administration
Low incidence of 
antiviral resistance
Long duration of 
treatment
Weak antiviral effect
Renal toxicity
12%
(93)*
NA 51%
(95)*
NA
Entecavir Oral administration
Strongest HBV inhibitor
Good tolerability
Low incidence of 
antiviral resistance
Long duration of 
treatment
High costs
21%
(102)*
NA 90%
(103)*
NA
this table shows mean response rates (HBeAg seroconversion for HBeAg-positive patients and undetectable HBV DNA for HBeAg-negative patients) 
at the end of treatment (Eot) with various antiviral drugs for 48 to 52 weeks and at the end of follow-up (EoFu) (NA = data not available). Response 
to therapy is less durable in HBeAg-negative patients compared with HBeAg-positive patients. Further, while (PEG-)IFN associated responses are 
generally durable, relapse occurs in a large proportion of nucleos(t)ide analogue treated patients after discontinuation of therapy. *References.
table 4. Predictors of response to antiviral therapy in HBeAg-positive patients
treatment Decreased likelihood of response Increased likelihood of response
(Peg)interferon Baseline ALAT ≤2 x ULN119
Baseline HBV DNA >109 c/ml64
Genotype C or D31-33
HIV coinfection121
Baseline ALAT >2 x ULN119
Baseline HBV DNA ≤109 c/ml64
Genotype A or B31-33
Nucleoside analogues Baseline ALAT ≤2 x ULN81
HAI 0-981
Baseline ALAT >2 x ULN81
HAI ≥1081
this table shows baseline factors influencing likelihood of response to antiviral therapy in HBeAg-positive patients.
ALAt = alanine aminotransferase; HBV = hepatitis B virus; uLN = upper limit of normal; HAI = histological activity index.
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since it may potentially precipitate immunological flares 
and liver failure in these patients (figure 2).73 Adverse events 
observed during treatment with PEG-IFN are similar to 
those observed with conventional IFN. The proportion of 
patients requiring discontinuation of treatment for safety 
reasons was comparable for PEG-IFN and standard IFN. 
levels detectable by non-PCR assays and seroconversion 
from HBeAg to anti-HBe has been achieved. However, 
lamivudine-induced HBeAg seroconversion is significantly 
less durable than HBeAg seroconversion following IFN-
containing therapies.82 Data on durability of response 
to lamivudine are limited, HBeAg seroconversion has 
been reported to be durable in 50 to 77% of patients.83,84 
Prolonged duration of ongoing lamivudine therapy after 
HBeAg seroconversion and low pretreatment HBV DNA 
seem to be associated with decreased relapse rates.83
In HBeAg-negative patients serum HBV DNA was 
undetectable by PCR assay in 68 to 73% of patients after 
one year of lamivudine therapy. At this time point 73 
to 96% of patients showed biochemical response.68,85,86 
However, relapse occurred in 66 to 85% of patients 
after discontinuation of treatment. In patients treated 
continuously over one year, response rates progressively 
declined to about 67% after two years, 60% after three 
years and 39% after four years.85,87,88 
Prolonged lamivudine treatment can be used to prevent 
adverse clinical outcome in patients with advanced 
liver disease (bridging fibrosis or cirrhosis). Disease 
progression, defined as a two-point increase in Child-
Turcotte-Pugh score, and development of HCC were found 
to be significantly decreased in lamivudine treated patients 
compared with untreated controls.42 
The major drawback of lamivudine, which significantly 
limits its use as first-line therapy, is the high rate of 
occurrence of viral resistance. The majority of patients 
with virological breakthrough show mutations in the 
tyrosine-methionine-aspartate-aspartate (YMDD) motif 
of the polymerase gene.88 The most important mutation 
is a substitution of valine or isoleucine for methionine 
at position 204 (rtM204V/I).89 In many patients this is 
accompanied by a second mutation substituting methionine 
for leucine in an upstream region (rtL180M). Lamivudine 
resistance is more likely to occur in patients with high 
baseline serum HBV DNA levels and patients with HBV 
DNA >103 c/ml after six months of treatment.90 The 
frequency of resistance increases with the duration of 
treatment from 24% at one year to 38% at two years, 50% 
at three years and 67% at four years.79,80,87 The emergence 
of lamivudine-resistant mutants is usually associated with 
an increase in serum HBV DNA and ALAT, and selection 
of YMDD variants has been associated with worsening of 
liver histology.91
Adefovir dipivoxil
Adefovir dipivoxil is the oral prodrug of adefovir and has 
activity against both wild-type and lamivudine-resistant 
HBV.92 Adefovir is a nucleotide analogue of adenosine 
monophosphate and acts as a competitive inhibitor and 
chain terminator of viral replication. Adefovir at the dose of 
10 mg daily is well tolerated and has a good safety profile.93
Figure 2. Host and virus induced flares associated 
with interferon therapy
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this figures shows serum HBV DNA ( ) and ALAt ( ) levels during 
and after (peg)interferon (IFN) therapy. IFN potentially induces 
immunological flares and liver failure: 1. Host-induced flare, with 
elevation in serum ALAt followed by a decrease in viral load. 
2. Virus-induced flare, where serum ALAt elevation is preceded by 
an increase in serum HBV DNA.122
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Lamivudine
Lamivudine was the first nucleoside analogue licensed for 
the treatment of chronic HBV. Lamivudine is a cytosine 
analogue and inhibits reverse transcriptase by competing 
for incorporation into growing DNA chains causing chain 
termination. Lamivudine can be taken orally in a dosage 
of 100 mg daily, is generally well tolerated and has an 
excellent safety profile.
HBeAg seroconversion with HBV DNA <105 c/ml occurs 
in 16 to 22% of patients by one year compared with 4 to 
13% of untreated controls.74-79 Higher cumulative HBeAg-
seroconversion rates were observed with increased duration 
of lamivudine treatment, with 29% at two years, 40% 
at three years, and 47% at four years of therapy.76,79,80 
Reduction of serum HBV DNA occurs in 98% of patients.75 
Elevated ALAT >2 x ULN was found to be the best predictor 
of response to lamivudine.81 Lamivudine treatment 
may be discontinued if HBV DNA is suppressed below 
181
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In HBeAg-positive patients, serum HBV DNA levels 
<103 c/ml and normalisation of ALAT were observed in 
21 and 48% of treated patients, compared with 0 and 16% 
of untreated controls after one year of adefovir therapy, 
respectively. HBeAg seroconversion occurred in 12% of 
patients receiving adefovir compared with 6% in the placebo 
group.93 Continued adefovir therapy over one year increased 
rates of HBeAg seroconversion to 29% after two years and 
43% after three years. A similar increase in the proportion of 
patients with HBV DNA <103 c/ml was observed, to 45 and 
56% of patients after 96 and 144 weeks, respectively.94
In HBeAg-negative patients, treatment with adefovir 
for one year resulted in serum HBV DNA <103 c/ml and 
normalisation of ALAT in 51 and 72% of treated patients, 
compared with 0 and 29% of untreated controls.95 The 
percentage of HBeAg-negative patients with HBV DNA 
<103 c/ml was 71% at two years and 67% at five years, 
and ALAT normalised in 73 and 69%, respectively.96,97 
Prolonged adefovir therapy significantly improved liver 
histology compared with baseline in up to 75 to 80% of 
patients after five years.96 Response to adefovir is generally 
not durable after discontinuation of treatment.95,97
Resistance to adefovir is less common and occurs later in 
the course of HBV treatment compared with lamivudine. 
To date, mutations in the polymerase gene that have 
been confirmed to confer resistance to adefovir include 
rtN236T and rtA181V.98 The rtN236T mutation occurs most 
frequently and is associated with the selection of a novel 
asparagine to threonine substitution at residue rt236 in the 
domain D of the HBV polymerase.97 The rtA181V mutation 
involves a substitution of alanine by valine or threonine at 
position rt181 of the B domain of the HBV polymerase. The 
cumulative probability of adefovir resistance is 0 and 28% 
at one and five years, respectively.96
Entecavir
Entecavir is a guanosine analogue and a potent inhibitor 
of the HBV polymerase. Entecavir has activity against both 
wild-type and lamivudine resistant HBV. Entecavir can be 
taken orally, is well tolerated and safe at daily dosages up to 
1 mg.99,100 Entecavir has recently been approved by the FDA 
for the treatment of chronic hepatitis B and should be given in 
a dosage of 0.5 mg daily in nucleoside analogue naive patients 
and 1 mg in lamivudine-refractory patients.100,101
In both HBeAg-positive and HBeAg-negative naive 
patients, one year of entecavir (0.5 mg daily) was found 
to be superior to lamivudine therapy in reducing serum 
HBV DNA (6.9 vs 5.4 log for HBeAg-positive and 5.0 vs 
4.5 log for HBeAg-negative patients, respectively) and 
histological improvement.102,103 HBeAg seroconversion, 
HBV DNA negativity by PCR assay and normalisation of 
ALAT were observed in 21, 67 and 68% of HBeAg-positive 
patients treated with entecavir for 48 weeks, respectively.102 
Prolonging entecavir therapy to 96 weeks resulted in HBeAg 
seroconversion in 31% and HBV DNA <102 c/ml in 80% of 
patients, respectively.104 In HBeAg-negative patients HBV 
DNA negativity by PCR assay occurred in 90% of patients, 
while 78% of patients had normalisation of ALAT at week 
48.103 In lamivudine-refractory patients treatment with 
entecavir 1 mg daily was superior to 0.5 mg daily, and resulted 
in HBeAg seroconversion in 4%, HBV DNA <102 c/ml in 26% 
and normalisation of ALAT in 68% of patients, respectively.101 
Based on these results, entecavir appears to be a stronger 
inhibitor of HBV than either lamivudine or adefovir.
Entecavir resistance requires pre-existing lamivudine 
resistance and additional changes at residue rtT184, rtS202 
or rtM250 of the HBV reverse transcriptase.105 Resistance 
to entecavir was not observed in nucleoside analogue naive 
patients treated with entecavir for 48 weeks or 96 weeks.106-108 
In lamivudine-refractory HBV resistance to entecavir has not 
been described after one year of therapy. However, changes 
at the rtT184 and/or rtS202 residue were observed in 10% of 
patients after two years of entecavir treatment.109
N E W  D R u G s
Emtricitabine is structurally similar to lamivudine (3TC) 
and has potent antiviral activity against HBV and human 
immunodeficiency virus (HIV). Seroconversion from HBeAg 
to anti-HBe can be observed in 12 to 23% of patients after 
48 weeks, increasing to 33% after 96 weeks of treatment.104,110 
In HBeAg-negative patients serum HBV DNA was <104 c/ml 
in 76 and 71% of patients after 48 weeks and 96 weeks 
of treatment, respectively.104 Mutations associated with 
resistance to emtricitabine were observed in 12 and 18% 
of patients after 48 weeks and 96 weeks of treatment, 
respectively.104 With the advent of newer antiviral agents with 
significantly lower risk of antiviral resistance, emtricitabine 
will possibly have a minor role as monotherapy for HBV.
Telbivudine is an L-nucleoside analogue, which is more 
potent than lamivudine in suppressing HBV DNA.111 Serum 
HBV DNA was undetectable by PCR assay in 61% of patients 
at week 52, while HBeAg seroconversion occurred in 31% 
of patients. Combination of telbivudine with lamivudine 
did not result in increased response rates. Resistance to 
telbivudine emerged in 5% of patients after one year of 
therapy. Ongoing phase III trials will help determine the 
role of telbivudine in the treatment of chronic HBV.
Tenofovir disoproxil fumarate is an acyclic nucleotide 
analogue and has been approved for the treatment of HIV 
infection. Dosage of tenofovir for hepatitis B infection is 
300 mg daily. Tenofovir seems more potent in suppression 
of HBV DNA than adefovir, with HBV DNA undetectable 
by PCR assay in all patients treated with tenofovir 
compared with 44% of patients treated with adefovir 
at week 48.112 Currently, randomised controlled trials 
comparing tenofovir and adefovir are being performed. 
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A N t I V I R A L  R E s I s t A N c E
The highest incidence antiviral resistance has been reported 
during lamivudine treatment,80 while resistance to adefovir 
and entecavir is less common.96,105 During nucleoside 
analogue treatment, close monitoring for antiviral resistance 
is advised, since hepatitis flares have been reported 
following lamivudine resistance. Antiviral resistance should 
be suspected if rebound of viral replication (1 log10 increase 
in serum HBV DNA) occurs in a fully compliant patient 
after initial response, antiviral resistance testing should 
then be considered (figure 3). It is still being debated 
whether combination nucleoside analogue treatment should 
be given, as for HIV infection, or subsequent introduction 
in case of nonresponse or resistance should be used. 
Prolonged combination therapy after emergence of antiviral 
resistance does not seem beneficial.113 However, whether a 
shorter overlap period of combination therapy is preferable 
in patients with advanced liver disease before discontinuing 
initial treatment has not been assessed. Sequential 
monotherapy may facilitate resistance to other drugs and 
may ultimately lead to multiresistance.109 Following that 
rationale, lamivudine treatment may negatively influence 
future treatment options due to the high incidence of 
antiviral resistance. Furthermore, a recent study showed 
decreased responsiveness of lamivudine-resistant patients 
to a course of PEG-IFN.114 Using lamivudine as initial 
therapy is therefore highly questionable. Currently adefovir 
is preferable as first-line nucleoside analogue therapy 
because of its favourable resistance profile. Entecavir and 
tenofovir seem to be the drugs with most potent anti-HBV 
activity and lowest rate of antiviral resistance discovered 
to date and may become the new standard in nucleos(t)ide 
analogue treatment for chronic hepatitis B.
V I R A L  s u P P R E s s I o N  o R  I M M u N E 
M o D u L A t I o N ?
The approach to treatment of hepatitis B has rapidly 
changed over the past decade. The treatment landscape 
has advanced with the availability of multiple new 
antiviral agents. However, despite this major progress, 
long-term off-treatment control has not been achieved in 
a large proportion of patients. Worldwide, evidence-based 
treatment guidelines for the management of chronic 
hepatitis B have been developed.3,22,115 These documents 
make few specific recommendations as to whether 
pegylated interferon or nucleoside analogues should be 
used as first-line therapy. Because both approaches have 
proven effective, but also have advantages and limitations, 
the question arises what treatment regime should be used 
as first-line therapy. The major difference between these 
treatment strategies is providing sustained off-treatment 
response with a finite treatment course (IFN) vs therapy-
maintained response (nucleoside analogues). 
Of currently available antiviral agents, peginterferon-based 
therapies result in the highest probability of sustained off-
treatment response. On the other hand, treatment with 
nucleoside analogues over prolonged periods is feasible and 
viral and biochemical response can generally be maintained. 
Since response to these agents is generally not durable 
after discontinuation of therapy, it is currently proposed 
that nucleoside analogue therapy needs to be continued 
indefinitely. This subsequently imposes a considerable 
risk for antiviral resistance. In our opinion, these findings 
provide a strong argument in favour of immunomodulatory 
therapy as first-line treatment for chronic hepatitis B. 
Irrespective of the type of antiviral therapy used, sustained 
virological response results in improved biochemical, 
histological and clinical outcome. The main goal of 
antiviral therapy in chronic hepatitis B therefore remains 
achieving sustained viral suppression, preferably with a 
finite course of therapy. Individual patient characteristics 
such as age, comorbid disorders and likelihood to tolerate 
potential side effects should also be included in deciding 
on the optimal treatment regime.
Since PEG-IFN results in the highest rates of off-
treatment response, treatment with this drug should 
be considered as first-line therapy in eligible patients 
with a high likelihood of response. This includes 
HBeAg-positive patients with genotype A or B, serum 
ALAT more than twice the upper limit of normal 
Figure 3. Selection of a mutant HBV associated with 
antiviral resistance
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this figure shows the emergence of hepatitis B virus variants 
associated with antiviral resistance during nucleos(t)ide analogue 
treatment. Antiviral resistance should be suspected if a 1log10 increase 
in serum HBV DNA ( ) is observed (*), this generally precedes rise in 
ALAt ( ) and detectability of resistant hepatitis B variants.
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and moderate HBV DNA levels (105 to 108 c/ml). 
Although data on PEG-IFN in HBeAg-negative chronic 
HBV are limited, PEG-IFN therapy may also be preferential 
in these patients. For patients with a low likelihood of 
response to or not eligible for PEG-IFN therapy, patients 
not tolerating PEG-IFN therapy, or with persistent hepatic 
inflammation and high viral load after a one-year course of 
PEG-IFN, treatment with nucleoside analogues should be 
considered. For several patient groups nucleoside analogues 
are the antiviral drug of choice. This includes patients 
with advanced cirrhosis, patients starting chemotherapy,116 
immunocompromised patients,117 and pregnant patients 
with very high HBV DNA levels (>109 c/ml).118
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